Zhejiang Huakang Pharmaceutical Co., Ltd. (SHA:605077)
China · Delayed Price · Currency is CNY 17.17
-0.81 (-4.51%)
May 28, 2026, 3:00 PM CST
SHA:605077 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 4,529 | 4,159 | 2,795 | 2,731 | 2,180 | 1,588 |
Other Revenue | 29.98 | 29.98 | 13.79 | 51.27 | 19.52 | 6.47 |
| 4,559 | 4,189 | 2,808 | 2,783 | 2,200 | 1,594 | |
Revenue Growth (YoY) | 52.47% | 49.15% | 0.92% | 26.48% | 38.02% | 20.79% |
Cost of Revenue | 3,975 | 3,581 | 2,198 | 2,111 | 1,696 | 1,227 |
Gross Profit | 584.46 | 607.74 | 610.82 | 671.82 | 503.69 | 367.13 |
Selling, General & Admin | 156.22 | 165.12 | 186.1 | 127.68 | 106.63 | 80.71 |
Research & Development | 157.36 | 144.92 | 128.41 | 124.28 | 99.71 | 84.23 |
Other Operating Expenses | 12.07 | 11.27 | 4.85 | 6.33 | -8.96 | 8.11 |
Operating Expenses | 320.96 | 316.64 | 335.89 | 262.97 | 204.27 | 178.96 |
Operating Income | 263.5 | 291.1 | 274.93 | 408.86 | 299.43 | 188.17 |
Interest Expense | -101.4 | -101.4 | -33.45 | -37.15 | -14.24 | -3.9 |
Interest & Investment Income | 29.06 | 23.96 | 32.12 | 28.27 | 48.53 | 57.7 |
Currency Exchange Gain (Loss) | 0.13 | 0.13 | 15.9 | 7.21 | 26.45 | -2.55 |
Other Non Operating Income (Expenses) | -34.64 | -1.67 | -1.07 | -0.86 | -4.84 | -0.44 |
EBT Excluding Unusual Items | 156.64 | 212.11 | 288.43 | 406.32 | 355.33 | 238.98 |
Gain (Loss) on Sale of Investments | -2.03 | 2.15 | -3.85 | 9.8 | -10.27 | 1.78 |
Gain (Loss) on Sale of Assets | 0.06 | 0.1 | -0.14 | -0.01 | 0.03 | 0.05 |
Asset Writedown | -3.33 | -0.47 | -0.49 | -4.27 | -2.31 | -1.39 |
Other Unusual Items | 12 | 12 | 2.61 | 10.56 | - | 14.64 |
Pretax Income | 163.34 | 225.89 | 286.57 | 422.4 | 342.78 | 254.07 |
Income Tax Expense | 19.54 | 23.18 | 17.78 | 50.02 | 23.5 | 17.36 |
Earnings From Continuing Operations | 143.81 | 202.7 | 268.79 | 372.38 | 319.28 | 236.71 |
Minority Interest in Earnings | -2.37 | -2.41 | -0.31 | -0.93 | - | - |
Net Income | 141.43 | 200.3 | 268.48 | 371.45 | 319.28 | 236.71 |
Net Income to Common | 141.43 | 200.3 | 268.48 | 371.45 | 319.28 | 236.71 |
Net Income Growth | -47.52% | -25.40% | -27.72% | 16.34% | 34.88% | -22.94% |
Shares Outstanding (Basic) | 308 | 303 | 298 | 297 | 296 | 288 |
Shares Outstanding (Diluted) | 308 | 303 | 378 | 297 | 296 | 288 |
Shares Change (YoY) | -17.96% | -19.74% | 27.25% | 0.23% | 3.09% | 28.98% |
EPS (Basic) | 0.46 | 0.66 | 0.90 | 1.25 | 1.08 | 0.82 |
EPS (Diluted) | 0.46 | 0.66 | 0.71 | 1.25 | 1.08 | 0.82 |
EPS Growth | -36.03% | -7.04% | -43.20% | 16.07% | 30.84% | -40.25% |
Free Cash Flow | -128.57 | -58.98 | -1,283 | -71.23 | -267.77 | -96.61 |
Free Cash Flow Per Share | -0.42 | -0.19 | -3.39 | -0.24 | -0.90 | -0.34 |
Dividend Per Share | 0.500 | 0.500 | 0.500 | 0.538 | 0.462 | 0.330 |
Dividend Growth | - | - | -7.15% | 16.68% | 40.02% | -16.02% |
Gross Margin | 12.82% | 14.51% | 21.75% | 24.14% | 22.89% | 23.03% |
Operating Margin | 5.78% | 6.95% | 9.79% | 14.69% | 13.61% | 11.80% |
Profit Margin | 3.10% | 4.78% | 9.56% | 13.35% | 14.51% | 14.85% |
Free Cash Flow Margin | -2.82% | -1.41% | -45.69% | -2.56% | -12.17% | -6.06% |
EBITDA | 576.31 | 581.57 | 476.08 | 581.7 | 404.88 | 272.57 |
EBITDA Margin | 12.64% | 13.88% | 16.95% | 20.90% | 18.40% | 17.10% |
D&A For EBITDA | 312.81 | 290.48 | 201.15 | 172.84 | 105.45 | 84.4 |
EBIT | 263.5 | 291.1 | 274.93 | 408.86 | 299.43 | 188.17 |
EBIT Margin | 5.78% | 6.95% | 9.79% | 14.69% | 13.61% | 11.80% |
Effective Tax Rate | 11.96% | 10.26% | 6.20% | 11.84% | 6.86% | 6.83% |
Revenue as Reported | 4,189 | 4,189 | 2,808 | 2,783 | 2,200 | 1,594 |
Advertising Expenses | - | 9.43 | 7.95 | 7.89 | 9.97 | 6.92 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.